A Safety Evaluation of MR-guided Focused Ultrasound Treatment for Palliative Pain Control of Bone Metastases

NCT ID: NCT03086824

Last Updated: 2017-03-22

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-12-12

Brief Summary

The purpose of this study is to investigate the safety and effectiveness of subjects receiving MR-guided Focused Ultrasound (MRgFUS) treatment for painful bone metastases. This study will evaluate treatment response and clinically significant adverse events. Other relevant data may be documented as well.

Detailed Description

This proposed study will be performed in full compliance with all applicable privacy rules and regulations, and their implementations at participating site(s). All subjects planned to undergo the MRgFUS procedure at Taipei Medical University Hospital will be offered informed consent so they can be included in this Study.

Conditions

Magnetic Resonance Guided Interventional Procedures

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

MRgFUS

Patients with painful bone metastases receiving magnetic resonance-guided focused ultrasound treatment.

Group Type: EXPERIMENTAL

magnetic resonance-guided focused ultrasound

Intervention Type: DEVICE

Interventions

magnetic resonance-guided focused ultrasound

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Men and women age 20 and older.

2. Patients who are able and willing to give consent and able to attend all study visits.

3. Patients who are suffering from symptoms of bone metastases: Patients who have received radiation without adequate relief from metastatic bone pain as determined by the patient and treating physician, those for whom their treating physician would not prescribe radiation or additional radiation treatments, and those patients who refuse additional radiation therapy.

4. Patient with NRS (0-10 scale) pain score ≥ 4 irrespective of medication.

5. Targeted bone/tumor interface are ExAblate device accessible and are located in ribs, extremities (excluding joints), pelvis, shoulders and in the posterior aspects of the following spinal vertebra: Lumbar vertebra (L3-L5), Sacral vertebra (S1-S5).

6. Patient whose targeted lesion is on bone and the interface between the bone and lesion is deeper than 10-mm from the skin.

7. Targeted (treated) tumor clearly visible by non-contrast MRI, and ExAblate MRgFUS device accessible.

8. Patients on ongoing chemotherapy regimen at the time of eligibility: 1) with same chemotherapy regimen (as documented from patient medical dossier, 2) worst pain NRS still ≥ 4, and 3) do NOT plan to initiate a new chemotherapy for pain palliation should be eligible for the study. Note: Planned multiple courses of chemotherapy are not considered New Chemotherapy.

9. No radiation therapy to targeted (most painful) lesion in the past two weeks.

10. Bisphosphonate intake should remain stable throughout the study duration. -

Exclusion Criteria

1. Patients who either Need surgical stabilization of the affected bony structure or Targeted tumor is at an impending fracture site or Surgical stabilization of tumor site with metallic hardware.

2. KPS (Karnofsky performance scale) Score < 60.

3. Unable to communicate sensations during the ExAblate treatment.

4. Target (treated) tumor is less then 10-mm from nerve bundles, bowels or bladder.

5. Patients with acute medical condition (e.g., pneumonia, sepsis) that is expected to hinder them from completing this study.

6. Severe cerebrovascular disease (multiple CVA or CVA within 6 months).

7. Patients with unstable cardiac status (e.g. unstable angina pectoris, myocardial infarction within 6 months, congestive heart failure NYHA Class IV, on arrhythmic drugs).

8. Severe hypertension (diastolic BP > 100 mmHg on medication).

9. Patients on dialysis.

10. Patients with standard contraindications for MRI or MRI contrast agents. -

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Taipei Medical University Shuang Ho Hospital

OTHER

Sponsor Role: lead

Responsible Party

Jo-Ting Tsai

Doctor of Philosophy(Ph.D.)/Director, Department of Radiation Oncology, Taipei Medical University - Shuang Ho Hospital, New Taipei, Taiwan

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Department of Radiation Oncology, Taipei Medical University Hospital

Taipei, Taiwan, Taiwan

Countries

Taiwan

Other Identifiers

TMU-SHH-2014-001

Identifier Type: -

Identifier Source: org_study_id